Design Therapeutics, Inc. (DSGN), will host an investor webcast today, May 18,2026, to review data from its RESTORE-FA clinical trial evaluating DT-216P2 in patients with Friedreich's ataxia.
Friedreich's ataxia (FA) is a rare inherited neurodegenerative disease. The company announced the webcast as part of its ongoing commitment to advance novel therapies for genetic disorders.
The RESTORE-FA trial is a Phase 1/2, open-label, multiple ascending dose study designed to evaluate the safety, tolerability, and pharmacokinetics of DT-216P2 in patients with Friedreich's ataxia. Participants enrolled in this study received subcutaneous or intravenous DT-216P2, with primary measures focused on treatment-emergent adverse events and secondary measures including drug exposure levels and frataxin expression changes over 12 weeks.
Frataxin is a mitochondrial protein essential for energy production, and restoring its levels is expected to help slow or stabilize disease progression.
DSGN has traded between $3.31 and $17.25 over the past year. The stock closed Friday's trading (May 15, 2026) at $14.37, down 1.17%. Dring overnight trading, the stock is at $15.93, up 10.86%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.